Amanda R Wasylishen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3324806/publications.pdf

Version: 2024-02-01

26	808	706676 14	651938 25
papers	citations	h-index	g-index

26	26	26	1803
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discovery, 2021, 11, 2094-2111.	7.7	66
2	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4969-e4980.	1.8	9
3	p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23663-23673.	3.3	26
4	Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Science Advances, 2020, 6, eaba8415.	4.7	22
5	Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6622-6629.	3.3	13
6	Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells. BMC Cancer, 2020, 20, 3.	1.1	10
7	Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17429-17437.	3.3	18
8	Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Research, 2019, 79, 2662-2668.	0.4	10
9	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 510-513.	0.5	9
10	Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 960-969.	3.3	13
11	CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death and Disease, 2018, 9, 1099.	2.7	50
12	p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer. Translational Oncology, 2018, 11, 930-940.	1.7	13
13	Daxx Functions Are p53-Independent In Vivo. Molecular Cancer Research, 2018, 16, 1523-1529.	1.5	12
14	Loss of digestive organ expansion factor (Diexf) reveals an essential role during murine embryonic development that is independent of p53. Oncotarget, 2017, 8, 103996-104006.	0.8	7
15	PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway. Oncotarget, 2016, 7, 18021-18035.	0.8	26
16	Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026211.	2.9	105
17	Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11145-11150.	3.3	77
18	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Research and Treatment, 2014, 143, 301-312.	1.1	52

#	Article	IF	Citations
19	Identification of c-MYC SUMOylation by Mass Spectrometry. PLoS ONE, 2014, 9, e115337.	1.1	18
20	MYC Phosphorylation at Novel Regulatory Regions Suppresses Transforming Activity. Cancer Research, 2013, 73, 6504-6515.	0.4	33
21	More than MAX: Discovering the Myc interactome. Cell Cycle, 2011, 10, 374-375.	1.3	11
22	Characterization of the apoptotic response of human leukemia cells to organosulfur compounds. BMC Cancer, 2010, 10, 351.	1.1	9
23	Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair. Cancer Research, 2010, 70, 8748-8759.	0.4	84
24	Myc: The Beauty and the Beast. Genes and Cancer, 2010, 1, 532-541.	0.6	61
25	Synthesis of the first Î± -mercaptoketal and an antifungal ketodisulfide. Journal of Sulfur Chemistry, 2008, 29, 163-170.	1.0	0
26	Inhibition of the Sodium/Potassium ATPase Impairs N-Glycan Expression and Function. Cancer Research, 2008, 68, 6688-6697.	0.4	54